Analyst Price Targets — GILD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:53 pm | — | Morgan Stanley | $175.00 | $140.34 | TheFly | Gilead price target raised to $175 from $171 at Morgan Stanley |
| April 8, 2026 12:24 pm | Gregory Renza | Truist Financial | $155.00 | $141.54 | TheFly | Gilead price target raised to $155 from $152 at Truist |
| March 10, 2026 9:37 am | Akash Tewari | Jefferies | $180.00 | $146.94 | StreetInsider | Jefferies Starts Gilead Sciences (GILD) at Buy |
| February 19, 2026 9:18 pm | — | Barclays | $155.00 | $151.12 | TheFly | Gilead initiated with an Equal Weight at Barclays |
| February 19, 2026 12:20 pm | — | Mizuho Securities | $170.00 | $152.74 | TheFly | Gilead price target raised to $170 from $140 at Mizuho |
| February 18, 2026 12:02 pm | — | UBS | $175.00 | $155.27 | TheFly | Gilead price target raised to $175 from $155 at UBS |
| February 11, 2026 2:28 pm | Louise Chen | Scotiabank | $177.00 | $155.29 | TheFly | Gilead price target raised to $177 from $140 at Scotiabank |
| February 11, 2026 2:27 pm | Courtney Breen | Bernstein | $160.00 | $155.45 | StreetInsider | Gilead Sciences (GILD) PT Raised to $160 at Bernstein SocGen Group |
| February 11, 2026 2:07 pm | — | Morgan Stanley | $171.00 | $155.72 | TheFly | Gilead price target raised to $171 from $150 at Morgan Stanley |
| February 11, 2026 1:36 pm | — | Truist Financial | $162.00 | $155.87 | StreetInsider | Gilead Sciences (GILD) PT Raised to $162 at BofA Securities |
Latest News for GILD
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bingham Private Wealth LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 11,530 shares of the biopharmaceutical company's stock, valued at approximately $1,415,000. Gilead Sciences accounts for 1.2% of
In the most recent trading session, Gilead Sciences (GILD) closed at $140.45, indicating a +1.02% shift from the previous trading day.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #EndHIV--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3…
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.